KRRO Korro Bio
- 33.610
- -1.110-3.20%
- 33.610
- 0.0000.00%
Korro Bio News
Korro to Participate in Upcoming June Investor and Scientific Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
Express News | HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Is Maintained at Outperform by BMO Capital
Korro Bio Is Maintained at Outperform by BMO Capital
Express News | BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target
Korro Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 140.19% BMO Capital → $120 Maintains Outperform 03/28/2024 130.18% HC Wainwright & Co. $100 → $
Piper Sandler Sticks to Its Buy Rating for Korro Bio (KRRO)
Korro Bio Earns Buy Rating From Analyst Mitchell Kapoor on Groundbreaking RNA Editing Technology and Strong Preclinical Results
Express News | Korro Bio, Inc. : H.c. Wainwright Cuts Target Price to $100 From $115
Express News | Korro Bio Inc Files for Offering of up to 1.2 Mln Common Shares by the Selling Stockholders - SEC Filing
Korro Bio Q1 2024 Adj EPS $(2.44) Beats $(2.51) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.51) by 2.79 percent.
Korro Bio | 10-Q: Quarterly report
Express News | Korro Bio Inc - Qtrly Shr Loss $2.44
Express News | Korro Bio Inc - Cash and Cash Equivalents Were $138.8 Million as of March 31, 2024
Express News | Korro Bio Inc - Cash Runway Into Second Half of 2026
Korro Bio Sees Cash Runway Into 2H of 2026 to Fund Anticipated Interim Readout of KRRO-110 and FIH Study Completion
Korro Bio Sees Cash Runway Into 2H of 2026 to Fund Anticipated Interim Readout of KRRO-110 and FIH Study Completion
Korro Names Kemi Olugemo, M.D. as Chief Medical Officer
Korro Names Kemi Olugemo, M.D. as Chief Medical Officer
Korro Bio 1Q Loss/Shr $2.44 >KRRO
Korro Bio 1Q Loss/Shr $2.44 >KRRO
Analysis
Price Target
No Data
